Company intelligence / Profile preview

Nuvalent

Cambridge, Massachusetts, United Statesnuvalent.com ↗

Ownership: Public · NUVL
Employees: ~125
Development stage: Phase 3

Overview

Nuvalent has demonstrated the ability to rationally design selective small molecule inhibitors for clinically validated kinase targets. Recent publications reinforce the potential of their lead candidate, zidesamtinib, as a novel ROS1-selective inhibitor. The company’s programs are advancing through clinical trials targeting cancers driven by specific genetic alterations and resistance mechanisms

Therapeutic areas: Oncology
Modalities: small molecules (precisely targeted kinase inhibitors)
Industry: Biotech

Drug pipeline

3 assets

zidesamtinib

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Not specified in provided sources.

Financials

Market cap: $9.1B
Total revenue: $0
Enterprise value: $7.8B

Beyond the preview

Go deeper on Nuvalent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvalent.

Explore the full profile